SYDNEY -- Novotech, a globally recognized full-service clinical research organization (CRO), announced that we have received the highly regarded Veeva Hero award presented at the 2025 Veeva R&D and Quality Summit in Seoul, South Korea.
Each year, Veeva recognizes industry-leading companies and organizations driving transformational change and growth as “Veeva Heroes.” This year, Novotech was recognized for its early and proactive adoption of Veeva platforms to streamline global clinical trials through strong collaboration across sponsors, CRO, and trial sites accelerating drug development and reinforcing its evolution from a regional leader to a global player.
“This recognition was made possible thanks to the dedication and hard work of our cross-functional internal Veeva team, whose efforts were instrumental in achieving this milestone,” stated Dr. Yooni Kim, Managing Director, Asia-Pacific. “Their commitment and collaborative spirit exemplify the core values that drive our success.”
The strategic collaboration between has significantly contributed to mutual growth in the Korean market, enabling biotech and pharma sponsors to accelerate product development and expedite the delivery of innovative therapies to patients. Novotech remains committed to advancing this partnership fostering innovation and driving excellence in clinical research.
